EICHOR

Recruiting studies: Metastatic Castrate Sensitive Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Canc
Phase N/A · 26 location(s) · AstraZeneca · NCT07052578 Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05956639 A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Phase 1 · 1 location(s) · Astellas Pharma Global Development, Inc. · NCT07339267 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · 395 location(s) · Canadian Cancer Trials Group · NCT06592924 Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Phase 3 · 25 location(s) · UNICANCER · NCT06496581 A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
Phase 3 · 18 location(s) · University College, London · NCT06320067 Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamid
Phase 3 · 56 location(s) · Alianza multidisciplinar para la investigación de los tumore · NCT07333066 Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Phase 2 · 12 location(s) · Sun Pharmaceutical Industries Limited · NCT05422911 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · 195 location(s) · Alliance for Clinical Trials in Oncology · NCT06931340 Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730 A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy a
Phase N/A · 1 location(s) · Bayer · NCT06661122 Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-rec
Phase 2 · 3 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06654336 Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06350825 An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Phase N/A · 1 location(s) · Bayer · NCT06334120 A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116 Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
NA · 7 location(s) · Karin Soderkvist · NCT04983095 A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitor
Phase N/A · 1 location(s) · Bayer · NCT07406282 This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · 341 location(s) · Pfizer · NCT07028853 The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer
Phase N/A · 2 location(s) · Uppsala University · NCT06446401 Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07290270 Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
Phase 2 · 12 location(s) · Fundacion Oncosur · NCT06582628 TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulm
Phase 1/Phase 2 · 31 location(s) · Novartis Pharmaceuticals · NCT07190300 A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Phase 2 · 52 location(s) · Astellas Pharma Global Development, Inc. · NCT07005154 Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Phase 1 · 12 location(s) · Vir Biotechnology, Inc. · NCT05997615 PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697 Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Phase 3 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05352178 Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
Phase 2 · 1 location(s) · University of Utah · NCT07216248 Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Phase N/A · 2 location(s) · Ankara Etlik City Hospital · NCT07181122 PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06652607 Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
NA · 1 location(s) · Paul Viscuse · NCT06429813

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →